Access to diverse, high-quality cancer imaging data remains one of the greatest challenges for European companies developing trustworthy AI for healthcare. Through the EUCAIM platform, SYCAI, a European MedTech SME specializing in AI solutions for abdominal imaging, is leveraging federated access to multi-centre datasets to validate and strengthen its CE-marked AI tools for hepatic and pancreatic disease detection.
A Streamlined Data User Experience
According to SYCAI, EUCAIM’s federated search capabilities have significantly simplified the process of identifying suitable cohorts across multiple data providers. By allowing searches by cancer type and imaging modality, the platform provides a single point of access to datasets that would otherwise require extensive individual outreach.
The centralized negotiation workflow has been especially valuable, enabling transparent communication with each data provider while allowing several access requests to be managed simultaneously. Interactions with providers such as INCISIVE have also helped SYCAI refine study designs, inclusion criteria, and technical requirements for federated execution.
Identifying Relevant Datasets Across Europe
SYCAI identified and requested access to eight datasets from three leading European cancer imaging initiatives through EUCAIM:
- CHAIMELEON: Colon Cancer, Prostate Cancer and Lung Cancer imaging and clinical datasets.
- INCISIVE: Colorectal cancer datasets.
- EuCanImage: Colorectal Liver Metastases (CRLM) Datasets 1 to 4.
For SYCAI, the most valuable resources are contrast-enhanced abdominal CT studies accompanied by clinical information and, where available, expert annotations. Since patients with colorectal, prostate, and lung cancer routinely undergo CT examinations that include the liver and pancreas, these datasets provide an important opportunity to validate AI tools on large, real-world, multi-centre populations. The EuCanImage CRLM datasets are particularly relevant for advancing liver lesion detection capabilities.
Expected Impact
SYCAI anticipates several important outcomes in the future:
- Independent multi-centre validation of its CE-marked liver and pancreas AI tools on populations not represented in the original training data.
- Stronger post-market clinical evidence to support clinical follow-up activities and future regulatory submissions.
- New scientific publications focusing on AI generalisation, uncertainty quantification, and calibration. This work will build upon SYCAI’s CURVAS Challenge at MICCAI 2024 and the resulting publication in Computers in Biology and Medicine (2025)
- New collaborations with data providers, researchers, and clinical partners across the EUCAIM ecosystem. SYCAI has also applied to the AI-BOOST Challenge 3 on generative AI for clinical datasets.
Why EUCAIM Matters for AI Innovation
For SMEs developing AI-powered medical technologies, obtaining access to diverse imaging data remains one of the largest barriers to creating clinically robust and regulatory-compliant solutions.
SYCAI highlights that EUCAIM provides a legitimate and well-governed route to accessing multi-centre data that would otherwise take years of individual agreements to secure. The platform’s federated approach allows algorithms to be brought to the data rather than moving data across institutions, supporting compliance with GDPR as well as SYCAI’s ISO 27001 and ISO 42001 information security and AI management processes.
This approach is essential for demonstrating that AI tools can perform consistently across different countries, healthcare systems, scanners, and acquisition protocols, generating the evidence needed to support CE-marked medical devices under the EU Medical Device Regulation (MDR).
Building Europe's Future Cancer Imaging Infrastructure
AI in cancer imaging can only deliver meaningful benefits to patients when models are trained and validated on data that reflects the diversity of Europe’s populations, healthcare institutions, and imaging equipment.
By providing a secure, trustworthy, and federated infrastructure for cancer imaging research, EUCAIM is helping lower barriers for SMEs, researchers, and innovators while promoting reproducible science and responsible AI development. Through initiatives such as SYCAI’s validation efforts, the platform is supporting the transition from promising AI prototypes to clinically validated tools capable of improving cancer detection and patient care across Europe.
Learn more about becoming a data user
Explore the EUCAIM catalogue